{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:19:34Z","timestamp":1779171574653,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/gt.2017.39","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T14:40:33Z","timestamp":1494859233000},"page":"498-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cure SMA and our patient community celebrate the first approved drug for SMA"],"prefix":"10.1038","volume":"24","author":[{"given":"J","family":"Glascock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Hobby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Jarecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"BFgt201739_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155\u2013165.","journal-title":"Cell"},{"key":"BFgt201739_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AH Burghes","year":"2009","unstructured":"Burghes AH, Beattie CE . Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 2009; 10: 597\u2013609.","journal-title":"Nat Rev Neurosci"},{"key":"BFgt201739_CR3","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999; 96: 6307\u20136311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFgt201739_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng854","volume":"30","author":"L Cartegni","year":"2002","unstructured":"Cartegni L, Krainer AR . Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002; 30: 377\u2013384.","journal-title":"Nat Genet"},{"key":"BFgt201739_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN . Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006; 26: 1333\u20131346.","journal-title":"Mol Cell Biol"},{"key":"BFgt201739_CR6","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","volume":"5","author":"Y Hua","year":"2007","unstructured":"Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR . Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 2007; 5: e73.","journal-title":"PLoS Biol"},{"key":"BFgt201739_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 2016; 86: 890\u2013897.","journal-title":"Neurology"},{"key":"BFgt201739_CR8","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017\u20133026.","journal-title":"Lancet"},{"key":"BFgt201739_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.nmd.2014.06.417","volume":"24","author":"B Darras","year":"2014","unstructured":"Darras B, Swoboda K, Iannaccone S, Montes J, Castro D, Holuba N et al. Results of a phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy. Neuromuscul Disord 2014; 24: 920.","journal-title":"Neuromuscul Disord"},{"key":"BFgt201739_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2016","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 2016; 81: 355\u2013368.","journal-title":"Ann Neurol"},{"key":"BFgt201739_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1053\/j.semperi.2015.03.006","volume":"39","author":"HC Phan","year":"2015","unstructured":"Phan HC, Taylor JL, Hannon H, Howell R . Newborn screening for spinal muscular atrophy: anticipating an imminent need. Semin Perinatol 2015; 39: 217\u2013229.","journal-title":"Semin Perinatol"},{"key":"BFgt201739_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mus.10050","volume":"25","author":"MB Bromberg","year":"2002","unstructured":"Bromberg MB, Swoboda KJ . Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 2002; 25: 445\u2013447.","journal-title":"Muscle Nerve"},{"key":"BFgt201739_CR13","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1093\/hmg\/ddr275","volume":"20","author":"TT Le","year":"2011","unstructured":"Le TT, McGovern VL, Alwine IE, Wang X, Massoni-Laporte A, Rich MM et al. Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet 2011; 20: 3578\u20133591.","journal-title":"Hum Mol Genet"},{"key":"BFgt201739_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","volume":"3","author":"SJ Kolb","year":"2016","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol 2016; 3: 132\u2013145.","journal-title":"Ann Clin Transl Neurol"},{"key":"BFgt201739_CR15","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1172\/JCI57291","volume":"121","author":"CM Lutz","year":"2011","unstructured":"Lutz CM, Kariya S, Patruni S, Osborne MA, Liu D, Henderson CE et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest 2011; 121: 3029\u20133041.","journal-title":"J Clin Invest"},{"key":"BFgt201739_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83: 810\u2013817.","journal-title":"Neurology"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201739","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:28:53Z","timestamp":1648560533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFgt201739"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.39","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]},"assertion":[{"value":"15 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JG, ML, KH and JJ are employees of Cure SMA, and have no financial interest in this or any SMA drug program. Cure SMA has a financial interest in this and other SMA drug programs","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}